Below are the financial statements of Royalty Pharma, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of USD | 2024 as of 2024-12-31 | 2023 as of 2023-12-31 |
|---|---|---|
| Assets | — | — |
| Current assets | — | — |
| Cash and cash equivalents | 929.03a | 477.01a |
| Financial royalty assets | 783.77a | 738.44a |
| Available for sale debt securities | 58.2a | 18.3a |
| Other royalty income receivable | 26.96a | 22.41a |
| Other current assets | 4.19a | 18.04a |
| Total current assets | 1,802.14a | 1,274.19a |
| Financial royalty assets, net | 15,127.16a | 14,088.66a |
| Equity securities | 186.96a | 199.49a |
| Available for sale debt securities | 693.5a | 437.1a |
| Equity method investments | 379.42a | 375.89a |
| Other assets | 33.53a | 6.52a |
| Total assets | 18,222.72a | 16,381.85a |
| Liabilities and shareholders’ equity | — | — |
| Current liabilities | — | — |
| Distributions payable to legacy non-controlling interests | 75.81a | 83.16a |
| Accounts payable and accrued expenses | 13.37a | 15.17a |
| Interest payable | 98.06a | 51.68a |
| Current portion of long-term debt | 997.77a | 0a |
| Other current liabilities | 68.6a | 11.38a |
| Total current liabilities | 1,253.62a | 161.38a |
| Long-term debt | 6,614.65a | 6,135.29a |
| Other liabilities | 12.08a | 0.9a |
| Total liabilities | 7,880.35a | 6,297.56a |
| Shareholders’ equity | — | — |
| Class A ordinary shares | 0.05a | 0.05a |
| Class B ordinary shares | 0a | 0a |
| Class R redeemable shares | 0.06a | 0.06a |
| Deferred shares | 0a | 0a |
| Additional paid-in capital | 4,103.48a | 4,011.44a |
| Retained earnings | 2,845.65a | 2,517.58a |
| Non-controlling interests | 3,395.79a | 3,557.79a |
| Treasury interests | -2.66a | -2.63a |
| Total shareholders’ equity | 10,342.37a | 10,084.29a |
| Total liabilities and shareholders’ equity | 18,222.72a | 16,381.85a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.